Get started
PROTHENA CORP PLC USD0.01PROTHENA CORP PLC USD0.01PROTHENA CORP PLC USD0.01

PROTHENA CORP PLC USD0.01

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals

0Y3M chart


Full chart

0Y3M upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪828.65 M‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−2.5 USD
Net income (FY)
‪−147.03 M‬ USD
Revenue (FY)
‪91.37 M‬ USD
Shares float
‪44.79 M‬
Beta (1Y)
0.83

Employees


Employees (FY)
173
Change (1Y)
+46 +36.22%
Revenue / Employee (1Y)
‪528.15 K‬ USD
Net income / Employee (1Y)
‪−849.87 K‬ USD

About Prothena Corporation plc


Sector
Health Technology
Industry
Biotechnology
CEO
Gene G. Kinney
Website
prothena.com
Headquarters
Dublin
Founded
2012
ISIN
IE00B91XRN20
FIGI
BBG00JWMXTG7
Prothena Corp. Plc is a clinical-stage neuroscience company, which engages in the discovery and development of novel therapies to change the course of devastating diseases. The firm’s clinical pipeline includes both wholly owned and partnered programs being developed for the potential treatment of diseases including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and other neurodegenerative diseases. The company was founded in December 1969 and is headquartered in Dublin, Ireland.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

0Y3M news



Ideas



See all ideas 

Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


The current price of 0Y3M is 14.9 USD — it has decreased by −0.93% in the past 24 hours. Watch PROTHENA CORP PLC USD0.01 stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on LSE exchange PROTHENA CORP PLC USD0.01 stocks are traded under the ticker 0Y3M.
0Y3M stock has risen by 19.04% compared to the previous week, the month change is a 2.97% rise, over the last year PROTHENA CORP PLC USD0.01 has showed a −60.51% decrease.
We've gathered analysts' opinions on PROTHENA CORP PLC USD0.01 future price: according to them, 0Y3M price has a max estimate of 94.00 USD and a min estimate of 22.00 USD. Watch 0Y3M chart and read a more detailed PROTHENA CORP PLC USD0.01 stock forecast: see what analysts think of PROTHENA CORP PLC USD0.01 and suggest that you do with its stocks.
0Y3M reached its all-time high on Sep 21, 2021 with the price of 77.6 USD, and its all-time low was 11.0 USD and was reached on Apr 26, 2018. View more price dynamics on 0Y3M chart.
See other stocks reaching their highest and lowest prices.
0Y3M stock is 6.44% volatile and has beta coefficient of 0.83. Track PROTHENA CORP PLC USD0.01 stock price on the chart and check out the list of the most volatile stocks — is PROTHENA CORP PLC USD0.01 there?
Today PROTHENA CORP PLC USD0.01 has the market capitalization of ‪828.65 M‬, it has increased by 9.19% over the last week.
Yes, you can track PROTHENA CORP PLC USD0.01 financials in yearly and quarterly reports right on TradingView.
PROTHENA CORP PLC USD0.01 is going to release the next earnings report on Feb 13, 2025. Keep track of upcoming events with our Earnings Calendar.
0Y3M earnings for the last quarter are −1.10 USD per share, whereas the estimation was −1.17 USD resulting in a 5.78% surprise. The estimated earnings for the next quarter are −1.02 USD per share. See more details about PROTHENA CORP PLC USD0.01 earnings.
PROTHENA CORP PLC USD0.01 revenue for the last quarter amounts to ‪970.00 K‬ USD, despite the estimated figure of ‪1.35 M‬ USD. In the next quarter, revenue is expected to reach ‪7.53 M‬ USD.
0Y3M net income for the last quarter is ‪−59.00 M‬ USD, while the quarter before that showed ‪66.89 M‬ USD of net income which accounts for −188.21% change. Track more PROTHENA CORP PLC USD0.01 financial stats to get the full picture.
No, 0Y3M doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 26, 2024, the company has 173.00 employees. See our rating of the largest employees — is PROTHENA CORP PLC USD0.01 on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. PROTHENA CORP PLC USD0.01 EBITDA is ‪−151.22 M‬ USD, and current EBITDA margin is −199.87%. See more stats in PROTHENA CORP PLC USD0.01 financial statements.
Like other stocks, 0Y3M shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade PROTHENA CORP PLC USD0.01 stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So PROTHENA CORP PLC USD0.01 technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating PROTHENA CORP PLC USD0.01 stock shows the sell signal. See more of PROTHENA CORP PLC USD0.01 technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.